Baxter International Inc.'s (BAX) Baxter BioScience has acquired SuppreMol GmbH for EUR 200 million, or about $225 million before working capital and other adjustments, the two companies said Wednesday.
SuppreMol is a privately-held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases.
The acquisition includes SuppreMol's early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders.
SuppreMol's pipeline includes lead candidate SM101, an investigational immunoregulatory treatment that has completed Phase 2a studies in idiopathic thrombocytopenic purpura or ITP, a disorder causing low platelet levels, and systemic lupus erythematosus or SLE, a disorder in which the immune system attacks healthy tissue.
In addition to the portfolio, Baxter also acquires and will continue to operate SuppreMol's operations in Munich.
For comments and feedback contact: editorial@rttnews.com
Business News